|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?显示文摘Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma(HCC) since 2007 and numerous studieshave investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC. | Giorgia Marisi Alessandro Cucchetti Paola Ulivi Matteo Canale Giuseppe Cabibbo Leonardo Solaini Francesco G Foschi Serena De Matteis Giorgio Ercolani Martina Valgiusti Giovanni L Frassineti Mario Scartozzi Andrea Casadei Gardini | 2018 | World Journal of Gastroenterology2018，24，36： | 14 |
| 2 | Molecular classifications of gastric cancers: Novel insights and possible future applications显示文摘Despite some notable advances in the systemic management of gastric cancer(GC), the prognosis of patients with advanced disease remains overall poor and their chance of cure is anecdotic. In a molecularly selected population, a median overall survival of 13.8 mo has been reached with the use of human epidermal growth factor 2(HER2) inhibitors in combination with chemotherapy, which has soon after become the standard of care for patients with HER2-overexpressing GC. Moreover, oncologists have recognized the clinical utility of conceiving cancers as a collection of different molecularlydriven entities rather than a single disease. Several molecular drivers have been identified as having crucial roles in other tumors and new molecular classifications have been recently proposed for gastric cancer as well. Not only these classifications allow the identification of different tumor subtypes with unique features, but also they serve as springboard for the development of different therapeutic strategies. Hopefully, the application of standard systemic chemotherapy, specifictargeted agents, immunotherapy or even surgery in specific cancer subgroups will help maximizing treatment outcomes and will avoid treating patients with minimal chance to respond, therefore diluting the average benefit. In this review, we aim at elucidating the aspects of GC molecular subtypes, and the possible future applications of such molecular analyses. | Silvio Ken Garattini Debora Basile Monica Cattaneo Valentina Fanotto Elena Ongaro Marta Bonotto Francesca V Negri Rosa Berenato Paola Ermacora Giovanni Gerardo Cardellino Mariella Giovannoni Nicoletta Pella Mario Scartozzi Lorenzo Antonuzzo Nicola Silvestris Gianpiero Fasola Giuseppe Aprile | 2017 | World Journal of Gastrointestinal Oncology2017，9，5： | 5 |
| 3 | Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options显示文摘 | Luca Faloppi Mario Scartozzi Elena Maccaroni Marzia Di Pietro Paolo Rossana Berardi Michela Del Prete Stefano Cascinu | 2010 | Cancer Treatment Reviews2010，，3： | 2 |
| 4 | Survey of 1 264 patients with orbital tumors and simulating lesions:The 2002 Montgomery lecture显示文摘 | Shields JA Shieldscl Scartozzi R | 2004 | Ophthalmology2004，111，5： | 1 |
| 5 | 5-fluorouracil pharmacogenomics: still rocking after all these years?显示文摘 | Mario Scartozzi Elena Maccaroni Riccardo Giampieri Mirco Pistelli Alessandro Bittoni Michela Del Prete Rossana Berardi Stefano Cascinu | 2011 | Pharmacogenomics2011，，2： | 1 |
| 6 | Phosphorylated Akt and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab显示文摘 | Scartozzi M Giampieri R Maccaroni E | 2012 | J Transl Med2012，10，1： | 1 |
| 7 | Survey of 1264 patients with orbital tumors and simulating lesions:The 2002 Montgomery Lecture,Part1显示文摘 | Shields JA Shields CL Scartozzi R | 2004 | Ophthalmology2004，111，5： | 1 |
| 8 | COX -2 and NF- KB overexpression is common in pancreatic cancer but does not predict for COX -2 inhibitors activity in combination with gemcitabine and oxaliplatin显示文摘 | Cascinu S Scartozzi M Carbonari G | 2007 | Am J Clin Oncol2007，30，5： | 1 |
| 9 | Roleof vascular endothelialgrowth factor (VEGF) andVEGF-R genotyping in guidingthe metastatic processin pT4 a resected gastriccancer patients显示文摘 | Mario Scartozzi Cristian Lorete11i Eva Galizia | 2012 | PloS one2012，7，7： | 1 |
| 10 | Nuclear factor-KB tumor expression predicts response and survival in irinotecan-refractory metastatic eolorectal cancer treated with cetuximabirinotecan therapy 显示文摘 | SCARTOZZI M BEARZI I PIERANTONI C | 2007 | J Clin Oncol2007，25，25： | 1 |
| 11 | Chemotherapy for locally advanced and metastatic gastric cancer:state of the art and future perapectives显示文摘 | Bittoni A Maccaroni E Scartozzi M | 2010 | Eur Rev Med Pharmacol Sci2010，14，2： | 1 |
| 12 | Chemotherapy for advanced gastric cancer:across the year for a standard of care显示文摘 | Scartozzi M Galizla E Verdecchia L | 2007 | Expert Opin Pharmacother2007，8，6： | 1 |
| 13 | Trans-arteriai chemo-embolization (TACE),with either lipiodol (traditional TACE) ordrug-eluting microspheres ( precision TACE,pTACE ) in thetreatment of hepatocellular carcinoma : efficacy and safety resultsfrom a large mono-institutional analysis 显示文摘 | Scartozzi M Baroni GS Faloppi L | 2010 | J Exp Clin CancerRes2010，29，1： | 1 |
| 14 | Survey of 1264 patients with orbital tumors and simulating lesions:the 2002 Montgomery Lecture,part 1显示文摘 | SHIELD J A SHIELDS C L SCARTOZZI R | 2004 | Ophthalmology2004，111，5： | 1 |
| 15 | Intraoperative Sclerotomy-related Retinal Breaks for Macular Surgery,20-vs 25-Gauge Vitrectomy Systems显示文摘 | Scartozzi R Bessa AS Gupta OP | 2007 | Am J Ophthalmol2007，143，： | 1 |
| 16 | High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)显示文摘 | Cascinu S Scartozzi M Labianca R | 2004 | Brit J Cancer2004，90，8： | 1 |
| 17 | Clinical predictive factors for advanced non-small cell lung cancer(NSCLC) patients receiving third-linetherapy:Seecting the unseleetable?显示文摘 | Scartozzi M Mazzanti P Giampieri R | 2010 | Lung Cancer2010，68，3： | 1 |
| 18 | Molecular biology ofsporadic gastric cancer: prognostic indicators and novel therapeuticapproaches 显示文摘 | Scartozzi M Galizia E Freddari F | 2004 | Cancer Treat Rev2004，30，5： | 1 |
| 19 | VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib:the ALICE-1study显示文摘 | Scartozzi M Faloppi L Svegliati Baroni G | 2014 | Int J Cancer2014，135，5： | 1 |
| 20 | The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management显示文摘 | Faloppi L Scartozzi M Bianconi M | 2014 | BMC Cancer2014，14，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员